The ME&MG Digital Solution for Autonomous Assessment of Myasthenia Gravis

Prior treatment

• Subjects having undergone thymectomy Plasma Exchange Therapy or Intravenous Immunoglobulin Therapy within four weeks of screening
• Subjects having initiated FcRn inhibitor therapy within the four weeks preceding screening
• Current drugs or/and alcohol abuse that could influence performance on the tests, as judged by the investigator
• Participant has participated in another clinical study within the previous 30 days of screening or is currently participating in another study that, in the opinion of the Investigator, might interfere with the subject's full participation in the study or confound the assessment of the subject or outcome of the study.

Other illness

• Known medical or psychological condition(s) or risk factor(s) that, as judged by the investigator, might interfere with the subject's full participation in the study, pose any additional risk for the subject, or confound the assessment of the subject or outcome of the study.

Other

• Pregnant and nursing women
• Person under guardianship or curatorship
• Participant included in another ME\&MG clinical study

• Aged over 18 Years
• Diagnosed with gMG at screening with generalized muscle weakness meeting the clinical criteria for diagnosis of MG, as defined by the MGFA Clinical Classification Class II, III, or IV, and likely not in need of a respirator for the duration of the study, as judged by the investigator
• With positive serologic testing for anti-AChR autoantibody at screening
• Have read the information sheet and signed the informed consent form
• Own a personal smartphone which software version is above 13 for IOS and 8 for Android included
• Able to use a smartphone
• Able to read language in which the mobile application is available (French, English, Spanish) and able to understand pictograms